Moonlight AI raised $3.3 million in private financing as it builds software to extract genomic biomarkers and disease signatures from routine imaging of blood and cytology smears. The Swiss diagnostic image-analysis startup said it will expand its whole-slide cytopathology library and link imaging to genomic data using clinical partners. The company plans to add employees and advance diagnostic programs in myelodysplastic syndrome, non-small cell lung cancer, and chronic lymphocytic leukemia. Moonlight AI’s strategy emphasizes scaling training datasets derived from real-world samples rather than relying solely on curated research imagery. The seed round was led by Lotus One Investment and VP Venture Partners, with participation from Medin Fund and other investors, according to the company. The financing highlights continued investor appetite for computational pathology tools that can connect traditional microscopy workflows to molecular readouts—an increasingly competitive area as companies race to commercialize AI-assisted biomarker detection.